Page 39 - ITPS-8-3

INNOSC Theranostics and
Pharmacological Sciences Benzodiazepine use and retention in OAT

34. MacCallum CA, Eadie L, Barr AM, Boivin M, Lu S. Practical 44. Hallowell BD, Chambers LC, Samuels EA, et al.
strategies using medical cannabis to reduce harms associated Sociodemographic and prescribing characteristics that
with long term opioid use in chronic pain. Front Pharmacol. impact long-term retention in buprenorphine treatment
2021;12(907):633168. for opioid use disorder among a statewide population. Drug
Alcohol Depend. 2022;241:109680.
doi: 10.3389/fphar.2021.633168
doi: 10.1016/j.drugalcdep.2022.109680
35. Tse L, Procyshyn RM, Fredrikson DH, Boyda HN,
Honer WG, Barr AM. Pharmacological treatment of 45. Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J,
antipsychotic-induced dyslipidemia and hypertension. Int Shaffer HJ, Albanese MJ. Benzodiazepine use during
Clin Psychopharmacol. 2014;29(3):125-137. buprenorphine treatment for opioid dependence: Clinical and
safety outcomes. Drug Alcohol Depend. 2013;132(3):580-586.
doi: 10.1097/YIC.0000000000000014
doi: 10.1016/j.drugalcdep.2013.04.006
36. Whitney Z, Procyshyn RM, Fredrikson DH, Barr AM.
Treatment of clozapine-associated weight gain: A systematic 46. Park TW, Larochelle MR, Saitz R, Wang N, Bernson D,
review. Eur J Clin Pharmacol. 2015;71(4):389-401. Walley AY. Associations between prescribed
benzodiazepines, overdose death and buprenorphine
doi: 10.1007/s00228-015-1807-1
discontinuation among people receiving buprenorphine.
37. Yuen JWY, Kim DD, Procyshyn RM, Panenka WJ, Addiction. 2020;115(5):924-932.
Honer WG, Barr AM. A focused review of the metabolic doi: 10.1111/add.14886
side-effects of clozapine. Front Endocrinol (Lausanne).
2021;12:609240. 47. Raffa JD, Grebely J, Tossonian H, et al. The impact of ongoing
illicit drug use on methadone adherence in illicit drug users
doi: 10.3389/fendo.2021.609240
receiving treatment for HIV in a directly observed therapy
38. Ray-Griffith S, Tharp E, Coker JL, Catlin D, Knight B, program. Drug Alcohol Depend. 2007;89(2-3):306-309.
Stowe ZN. Buprenorphine medication for opioid use doi: 10.1016/j.drugalcdep.2007.02.007
disorder: A study of factors associated with postpartum
treatment retention. Am J Addict. 2021;30(1):43-48. 48. White WL, Campbell MD, Spencer RD, Hoffman HA,
Crissman B, DuPont RL. Patterns of abstinence or continued
doi: 10.1111/ajad.13084
drug use among methadone maintenance patients and
39. Morford KL, Tetrault JM, Zhou B, et al. The impact of their relation to treatment retention. J Psychoactive Drugs.
benzodiazepine exposure on treatment retention in an 2014;46(2):114-122.
open-access methadone program: A retrospective cohort doi: 10.1080/02791072.2014.901587
study. Drug Alcohol Depend. 2022;241:109707.
49. Eibl JK, Wilton AS, Franklyn AM, Kurdyak P, Marsh DC.
doi: 10.1016/j.drugalcdep.2022.109707
Evaluating the Impact of prescribed versus nonprescribed
40. Brands B, Blake J, Marsh DC, Sproule B, Jeyapalan R, Li S. The benzodiazepine use in methadone maintenance therapy:
impact of benzodiazepine use on methadone maintenance Results from a population-based retrospective cohort study.
treatment outcomes. J Addict Dis. 2008;27(3):37-48. J Addict Med. 2019;13(3):182-187.
doi: 10.1080/10550880802122620 doi: 10.1097/adm.0000000000000476
41. Durand L, Boland F, O’Driscoll D, et al. Factors associated 50. Peles E, Adelson M, Schreiber S. Benzodiazepine usage
with early and later dropout from methadone maintenance during 19.5 years in methadone maintenance treatment
treatment in specialist addiction clinics: A six-year cohort patients and its relation to long-term outcome. Isr J
study using proportional hazards frailty models for recurrent Psychiatry Relat Sci. 2014;51(4):285-288.
treatment episodes. Drug Alcohol Depend. 2021;219:108466.
51. Montalvo C, Stankiewicz B, Brochier A, Henderson DC,
doi: 10.1016/j.drugalcdep.2020.108466 Borba CPC. Long-term retention in an outpatient
behavioral health clinic with buprenorphine. Am J Addict.
42. Franklyn AM, Eibl JK, Gauthier G, Pellegrini D,
Lightfoot NE, Marsh DC. The impact of benzodiazepine use 2019;28(5):339-346.
in patients enrolled in opioid agonist therapy in Northern doi: 10.1111/ajad.12896
and rural Ontario. Harm Reduct J. 2017;14(1):6.
52. Taha SA, Westra JR, Tacker DH, Raji MA, Kuo YF. Trends in
doi: 10.1186/s12954-017-0134-5 co-prescribed opioids and benzodiazepines, non-prescribed
opioids and benzodiazepines, and schedule-I drugs in the
43. Dayal P, Balhara YPS, Mishra AK. An open label naturalistic
study of predictors of retention and compliance to United States, 2013 to 2019. Prev Med Rep. 2024;38:102584.
naltrexone maintenance treatment among patients with doi: 10.1016/j.pmedr.2023.102584
opioid dependence. J Subst Use. 2016;21(3):309-316.
53. Hutchison RW, Carhart J. Opioid and benzodiazepine
doi: 10.3109/14659891.2015.1021867 utilization patterns in metropolitan and rural Texas. J Opioid

Volume 8 Issue 3 (2025) 33 doi: 10.36922/itps.5151